A

mid ongoing concern over clinical trial disclosure, a new analysis finds that drug makers are doing a better job of making data available compared with the last spot check two years ago, although there is still room for improvement.

In reaching this conclusion, the researchers examined 505 trials for 19 novel new drugs that were approved in 2014 by the Food and Drug Administration and that were sponsored by 11 large drug makers. They found the public availability of results for each drug increased. The median disclosure rate of trials conducted in patients, for each drug, went up from a median fo 87 percent to 96 percent, when measured 13 months after approval.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy